Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
about
Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic ReviewInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemAntiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuriaActive vitamin D treatment for reduction of residual proteinuria: a systematic review.Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD).Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?Vitamin D receptor activation and cardiovascular disease.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013?Government Quality Measures: First Do No Harm.Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.The beneficial impact of vitamin D treatment in CKD patients: what's next?Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients.Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.Approach to cardiovascular disease prevention in patients with chronic kidney disease.Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.Treating endothelial dysfunction with vitamin D in chronic kidney disease: a meta-analysis
P2860
Q26774371-95115610-3FBB-48A3-8BF9-1887E122694BQ26822500-D69D4E83-DCA4-43CA-8920-1082EBB50CEEQ34483554-3CF63EA0-45C0-4D66-89D0-5C0DA5016EFAQ34505057-8B80F94B-8741-4C3D-B4D6-7F49768246C2Q34610602-B296A91B-7936-442A-B542-E96F62A9C20FQ34760971-E1D34F2E-D291-405A-837E-C6D0468D1BE9Q34912750-DF2F66DB-E908-4F4D-A695-234F9BB9FDA5Q35608454-88F0D3BA-DC59-4C23-9BB9-948E6B7ECAF7Q36613869-48DA7C00-2D8B-4266-8EEC-848F76E59B0CQ37620414-E929D4A0-093A-4FB2-9371-E36F7297BB35Q37729792-54A52765-6A3F-4F4F-9A15-EF0BDC31643BQ38069143-2C9E2E1D-DD9C-4694-8A05-90352A2934CEQ38092144-D58D3C7F-1360-428D-8274-816B95C98EF4Q38156665-6AE21018-FA2C-4FE6-8E6A-45D15928430EQ38566172-4D535398-E432-4771-B67B-1995441AE450Q38691202-29306788-DEF7-46C7-B4D6-31AE8E61A306Q41542599-2C6DC8CA-DF08-4ABA-9031-B1194D6B6B36Q41845704-96981403-1DAB-497B-929F-33A9C0BBAA5CQ43233976-14767598-4F6F-4513-9937-D2701776B2D8Q48047762-ED79C3E9-72D0-4D29-A2F2-65751BA89766Q48242270-FF2ED5F2-1963-4863-A333-595836B9B3E4Q49136022-432CD92F-0516-4024-AFF1-75013F3910F2Q51823258-8F713EE4-51B2-4CA7-9781-E6521DF739BEQ58698417-EE12EFBD-4BEE-4E64-924F-C6FB510B36AC
P2860
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@ast
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@en
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@nl
type
label
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@ast
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@en
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@nl
prefLabel
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@ast
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@en
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@nl
P2093
P356
P1476
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
@en
P2093
Jianghua Chen
Xiaohui Zhang
P304
P356
10.2215/CJN.03000311
P577
2012-01-05T00:00:00Z